Sakar Healthcare has entered into an agreement with the Swiss pharmaceutical major - Ferring Pharmaceuticals and Bazell Pharma LLP for developing the novel drug delivery system (NDDS) for two of the oncology products. Both the products are prescription medicine in segment of oncology- one is androgen biosynthesis inhibitors while the other being first triple-acting, androgen receptor antagonist. Both are extensively used to treat Prostate cancer- while the patented one in liquid sachet is for prostate cancer that has metastasized, the other innovative one in sachet powder is to block testosterone to reach prostate cancer cells. The present worldwide market size for general prostate therapeutics is $12.12 billion, expected to be $21.48 billion by 2030- with a CAGR of 8.4%.
Sakar has initiated for the development of the product and scale up batches at its research-driven API integrated oncology formulation-manufacturing unit at Bavla, near Ahmedabad, Gujarat, India. This back-to-back contract confirms Sakar's capabilities towards product development, process optimization, technology management skills, analytical documentation with cytotoxic products that helped perceive concept towards delivery of products, with exclusive worldwide supply.
Sakar Healthcare is an Indian pharmaceutical company engaged in the manufacturing and marketing of its own pharmaceutical formulations for domestic and international markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: